MedWatch

Roche's hemophilia treatment well on the way to triple blockbuster status

The acceleration in sales of Roche's Hemlibra, which competes with Novo Nordisk in an increasingly hot market, has continued. Sales for the first half year totaled more than USD 1.5bn.

Photo: Michael Buholzer/Reuters/Ritzau Scanpix

At the six-month mark of 2021, total sales at Roche can be seen to have acellerated after a slightly slow start, reaching CHF 14.8bn (USD 16bn) for Q2 and CHF 30.71bn (USD 33.46bn) for the first half of the year.

Although sales of pharmaceutical products have experienced setbacks during the first two quarters, Hemlibra is one of the newer drugs that has done well.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs